Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study Overall, 210 evaluable patients (n = 456 consented) ...
Absci Corporation (ABSI) is working on developing the use of its biological drug ABS-101 for the treatment of patients with inflammatory bowel disease [IBD]. This drug is already de-risked in the fact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results